TABLE 2.
One-year outcomes for patients stratified at M1 or M3.
| Characteristic | Full cohort n = 551 | M1 | M3 | ||||
|---|---|---|---|---|---|---|---|
| FM n = 250 | IM & SM n = 293 | p | FM n = 164 | IM & SM n = 321 | p | ||
| Graft failure | 10 (1.8%) | 4 (1.6%) | 6 (2.0%) | ns | 1 (0.6%) | 5 (1.6%) | ns |
| Death | 5 (0.9%) | 2 (0.8%) | 2 (0.7%) | ns | 2 (1.2%) | 3 (0.9%) | ns |
| BKVN | 27 (4.9%) | 10 (4.0%) | 17 (5.8%) | ns | 5 (3.0%) | 20 (6.2%) | ns |
| BKV viremia | 111 (20.1%) | 56 (22.4%) | 55 (18.8%) | ns | 25 (15.2%) | 64 (19.9%) | ns |
| Before M1 | 6 (5.4%) | 3 (5.4%) | 3 (5.5%) | 0 (0.0%) | 5 (7.8%) | ||
| M3 | 39 (35.1%) | 21 (37.5%) | 18 (32.7%) | 10 (40.0%) | 24 (37.5%) | ||
| M6 | 77 (69.4%) | 38 (67.9%) | 39 (70.1%) | 15 (60.0%) | 42 (65.6%) | ||
| M12 | 111 (100.0%) | 56 (100.0%) | 55 (100.0%) | 25 (100.0%) | 64 (100.0%) | ||
| CMV organ infection | 12 (2.2%) | 5 (2.0%) | 7 (2.4%) | ns | 2 (1.2%) | 8 (2.5%) | ns |
| CMV viremia | 139 (25.2%) | 66 (26.4%) | 73 (24.9%) | ns | 41 (25.0%) | 83 (25.9%) | ns |
| Before M1 | 24 (17.3%) | 10 (15.2%) | 14 (19.2%) | 7 (17.1%) | 14 (16.9%) | ||
| M3 | 61 (43.9%) | 29 (44.0%) | 32 (43.8%) | 21 (51.2%) | 32 (38.6%) | ||
| M6 | 89 (64.0%) | 43 (65.2%) | 46 (63.0%) | 28 (68.3%) | 50 (60.2%) | ||
| M12 | 139 (100.0%) | 66 (100.0%) | 73 (100.0%) | 41 (100.0%) | 83 (100.0%) | ||
| BPAR | 172 (31.2%) | 91 (36.4%) | 79 (27.0%) | * | 72 (43.9%) | 83 (25.9%) | **** |
| Before M1 | 96 (55.8%) | 55 (60.4%) | 40 (50.6%) | 44 (61.1%) | 43 (51.8%) | ||
| M3 | 131 (76.2%) | 68 (74.7%) | 61 (77.2%) | 56 (77.8%) | 64 (77.1%) | ||
| M6 | 156 (90.7%) | 83 (91.2%) | 71 (89.9%) | 66 (91.7%) | 75 (90.3%) | ||
| M12 | 172 (100.0%) | 91 (100.0%) | 79 (100.0%) | 72 (100.0%) | 83 (100.0%) | ||
| eGFR (mean ± SD) | |||||||
| M1 | 44.5 (±16.8) | 44.9 (±17.6) | 44.2 (±16.0) | ns | 43.3 (±16.7) | 44.8 (±17.0) | ns |
| M3 | 44.4 (±16.4) | 45.1 (±17.4) | 43.8 (±15.6) | ns | 44.2 (±16.9) | 44.5 (±16.2) | ns |
| M6 | 46.1 (±16.4) | 44.8 (±16.5) | 47.2 (±16.4) | ns | 43.1 (±16.4) | 47.3 (±16.0) | * |
| M12 | 48.7 (±19.1) | 47.8 (±22.1) | 49.2 (±16.1) | ns | 45.4 (±18.9) | 50.6 (±19.3) | ** |
All patients with calculable C/D ratios at the respective times were included in this analysis. Significance as indicated: ns p-value ≥0.05, * p-value <0.05, ** p-value <0.01, *** p-value <0.001, **** p-value <0.0001. BKV, BK virus; BKVN, BKV nephritis; BPAR, biopsy-proven acute graft rejection; CMV, cytomegalovirus; eGFR, estimated glomerular filtration rate (in mL/min/1.73 m2); FM, fast metabolizer; IM, intermediate metabolizer; M1/3/6/12, 1/3/6/12 months post-transplantation; ns, not significant; SD, standard deviation; SM, slow metabolizer.